Sepsis: Rethinking the approach to clinical research

Journal of Leukocyte Biology

Volumn 83, Issue 3, 2008, Pages 471-482

  Marshall, John C ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Clinical trials; Innate immunity; TNF; Toll like receptors; Translational research

Indexed keywords

ANTISERUM; METHYLPREDNISOLONE; N(G) METHYLARGININE; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; BLOOD CLOTTING FACTOR; CYTOKINE; PLACEBO;

CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE COURSE; DOWN REGULATION; DRUG INHIBITION; DRUG MEGADOSE; ENTERITIS; GRAM NEGATIVE AEROBIC RODS AND COCCI; HISTORY OF MEDICINE; HUMAN; IMMUNE RESPONSE; INCIDENCE; INNATE IMMUNITY; INTERVENTION STUDY; MORBIDITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; TREATMENT PLANNING; BACTERIAL INFECTION; INFECTION; INFLAMMATION; MICROBIOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

BACTERIAL INFECTIONS; BLOOD COAGULATION FACTORS; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; INFECTION; INFLAMMATION; PLACEBOS; SEPSIS; SIGNAL TRANSDUCTION;

EID: 43349108280     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0607380     Document Type: Conference Paper

References (81)

1. Majno, G. (1991) The ancient riddle of (sepsis). J. Infect. Dis. 163, 937-945.
2. Michalek, S. M., Moore, R. N., McGhee, J. R., Rosenstreich, D. L., Mergenhagen, S. E. (1980) The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J. Infect. Dis. 141, 55-63.
3. Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H., Braude, A. I. (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307, 1225-1230.
4. Marshall, J. C. (2003) Such stuff as dreams are made on: mediator-targeted therapy in sepsis. Nat. Rev. Drug Discov. 2, 391-405.
5. Vincent, J-L., Sun, Q., Dubois, M-J. (2002) Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34, 1084-1093.
6. Bernard, G. R., Vincent, J-L., Laterre, P. F., LaRosa, S. P., Dhainaut, J-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., Fisher Jr., C. J., Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709.
7. Eichacker, P. Q., Natanson, C. (2003) Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit. Care Med. 31 (Suppl. 1), S94-S96.
8. Annane, D., Sebille, V., Charpentier, C., Bollaert, P-E., Francois, B., Korach, J-M., Capellier, G., Cohen, Y., Azoulay, E., Troche, G., et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288, 862-871.
9. Turgeon, A. F., Hutton, B., Fergusson, D. A., McIntyre, L., Tinmouth, A. A., Cameron, D. W., Hébert, P. C. (2007) Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann. Intern. Med. 146, 193-203.
10. Panacek, E. A., Marshall, J. C., Albertson, T. E., Johnson, D. H., Johnson, S. B., MacArthur, R. D., Miller, M. A., Barchuk, W. T., Fischkoff, S., Kaul, M., et al. (2004) Efficacy and safety of the monoclonal anti-TNF antibody F(ab′)2 fragment in patients with severe sepsis stratified by IL-6 level. Crit. Care Med. 32, 2173-2182.
11. Friedrich, J. O. (2006) Drotrecogin α (activated) in severe sepsis. N. Engl. J. Med. 354, 94-96.
12. Bone, R. C., Fisher, C. J., Clemmer, T. P., Slotman, G. J., Metz, C. A., Balk, R. A. (1989) Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit. Care Med. 17, 389-393.
13. Bone, R. C., Fisher, C. J., Clemmer, T. P., Slotman, G. J., Metz, C. A., Balk, R. A. (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317, 653-658.
14. Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., Sibbald, W. J. (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-1655.
15. Casey, L. C., Balk, R. A., Bone, R. C. (1993) Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119, 771-778.
16. Bates, D. W., Parsonnet, J., Ketchum, P. A., Miller, E. B., Novitsky, T. J., Sands, K., Hibberd, P. L., Graman, P. S., Lanken, P. N., Schwartz, J. S., et al. (1998) Limulus amebocyte lysate assay for detection of endotoxin in patients with sepsis syndrome. AMCC Sepsis Project Working Group. Clin. Infect. Dis. 27, 582-591.
17. Roumen, R. M. H., Frieling, J. T. M., van Tits, H. W., van der Vliet, J. A., Goris, R. J. (1993) Endotoxemia after major vascular operations. J. Vasc. Surg. 18, 853-857.
18. Buttenschoen, K., Berger, D., Hiki, N., Buttenschoen, D. C., Vasilescu, C., Chikh-Torab, F., Seidelmann, M., Beger, H. G. (2000) Endotoxin and antiendotoxin antibodies in patients with acute pancreatitis. Eur. J. Surg. 166, 459-466.
19. Marshall, J. C., Foster, D., Vincent, J-L., Cook, D. J., Dellinger, R. P., Opal, S., Abraham, E., Brett, S., Smith, T., Mehta, S., Derzko, A., Romaschin, A. (2004) Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J. Infect. Dis. 190, 527-534.
20. Beutler, B., Milsark, I. W., Cerami, A. C. (1985) Passive immunization against cachectin tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869-871.
21. Poltorak, A., He, X., Smirnova, I., Liu, M-Y., van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in the Tlr4 gene. Science 282, 2085-2088.
22. Anderson, K. V., Jürgens, G., Nüsslein-Vollhard, C. (1985) Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 42, 779-789.
23. Akira, S., Uematsu, S., Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell 124, 783-801.
24. Marson, A. L., Tarr, D. E., Scott, A. L. (2001) Macrophage migration inhibitory factor (MIF) transcription is significantly elevated in Caenorhabditis elegans dauer larvae. Gene 278, 53-62.
25. Yuan, J. Y., Horvitz, H. R. (1990) The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. Dev. Biol. 138, 33-41.
26. Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A., Yuan, J. (1993) Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75, 653-660.
27. Nhan, T. Q., Liles, W. C., Schwartz, S. M. (2006) Physiological functions of caspases beyond cell death. Am. J. Pathol. 169, 729-737.
28. Muller, W. E., Perovic, S., Wilkesman, J., Kruse, M., Muller, I. M., Batel, R. (1999) Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with zenogeneic sponge molecule(s). DNA Cell Biol. 18, 885-893.
29. Jia, S. H., Li, Y., Parodo, J., Kapus, A., Fan, L., Rotstein, O. D., Marshall, J. C. (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 113, 1318-1327.
30. Martin, P. R., Shea, R. J., Mulks, M. H. (2001) Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J. Bacteriol. 183, 1168-1174.
31. Calvano, S. E., Xiao, W., Richards, D. R., Felciano, R. M., Baker, H. V., Cho, R. J., Chen, R. O., Brownstein, B. H., Cobb, J. P., Tschoeke, S. K., et al. (2005) A network-based analysis of systemic inflammation in humans. Nature 437, 1032-1037.
32. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J. M., Hoffmann, J. A. (1996) The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86, 973-983.
33. O'Neill, L. A., Bowie, A. G. (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling. Nat. Rev. Immunol. 7, 353-364.
34. Seong, S. Y., Matzinger, P. (2004) Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469-478.
35. Sansonetti, P. J. (2006) The innate signaling of dangers and the dangers of innate signaling. Nat. Immunol. 7, 1237-1242.
36. Miyake, K. (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 19, 3-10.
37. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., Medzhitov, R. (2004) Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 118, 229-241.
38. Lee, J., Mo, J. H., Shen, C., Rucker, A. N., Raz, E. (2007) Toll-like receptor signaling in intestinal epithelial cells contributes to colonic homoeostasis. Curr. Opin. Gastroenterol. 23, 27-31.
39. Lorente, J. A., Marshall, J. C. (2005) Neutralization of tumor necrosis factor (TNF) in pre-clinical models of sepsis. Shock 24 (Suppl. 1), 107-119.
40. Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., Montori, V. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285.
41. Schaedler, R. W., Dubos, R. J. (1962) The fecal flora of various strains of mice. Its bearing on their susceptibility to endotoxin. J. Exp. Med. 115, 1149-1159.
42. Marshall, J. C., Deitch, E. A., Moldawer, L. L., Opal, S., Redl, H., van der Poll, T. (2005) Pre-clinical models of sepsis: what can they tell us? Shock 24 (Suppl. 1), 107-119.
43. Aarts, M. A., Granton, J., Cook, D., Bohnen, J., Marshall, J. C. (2007) Empiric antimicrobial therapy in critical illness: results of a surgical infection society survey. Surg. Infect. (Larchmt) 8, 329-336.
44. Takeuchi, O., Akira, S. (2007) Signaling pathways activated by microorganisms. Curr. Opin. Cell Biol. 19, 185-191.
45. O'Neill, L. A., Dunne, A., Edjeback, M., Gray, P., Jefferies, C., Wietek, C. (2003) Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors. J. Endotoxin Res. 9, 55-59.
46. Khor, C. C., Chapman, S. J., Vannberg, F. O., Dunne, A., Murphy, C., Ling, E. Y., Frodsham, A. J., Walley, A. J., Kyrieleis, O., Khan, A., et al. (2007) A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat. Genet. 39, 523-528.
47. Branger, J., van den Blink, B., Weijer, S., Gupta, A., van Deventer, S. J., Hack, C. E., Peppelenbosch, M. P., van der Poll, T. (2003) Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 101, 4446-4448.
48. Lynn, M., Rossignol, D. P., Wheeler, J. L., Kao, R. J., Perdomo, C. A., Noveck, R., Vargas, R., D'Angelo, T., Gotzkowsky, S., McMahon, F. G. (2003) Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J. Infect. Dis. 187, 631-639.
49. Martin, G. S., Mannino, D. M., Eaton, S., Moss, M. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554.
50. Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., Pinsky, M. R. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310.
51. Muckart, D. J., Bhagwanjee, S. (1997) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit. Care Med. 25, 1789-1795.
52. Rangel-Frausto, M. S., Pittet, D., Costigan, M., Hwang, T., Davis, C. S., Wenzel, R. P. (1995) The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 273, 117-123.
53. Marshall, J. C., Sweeney, D. (1990) Microbial infection and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Arch. Surg. 125, 17-22.
54. Kannel, W. B. (1999) Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am. Heart J. 138, 205-210.
55. Gospodarowicz, M., Benedet, L., Hutter, R. V., Flemimg, I., Henson, D. E., Sobin, L. H. (1998) History and international developments in cancer staging. Cancer Prev. Control 2, 262-268.
56. Wheeler, A. P., Bernard, G. R. (2007) Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 369, 1553-1564.
57. (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N. Engl. J. Med. 342, 1301-1308.
58. Ranieri, V. M., Suter, P. M., Tortorella, C., de Tullio, R., Dayer, J. M., Brienza, A., Bruno, F., Slutsky, A. S. (1999) Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome. A randomized controlled trial. JAMA 282, 54-61.
59. Imai, Y., Parodo, J., Kajikawa, O., de Perrot, M., Fischer, S., Edwards, V., Cutz, E., Liu, M., Keshavjee, S., Martin, T. R., et al. (2003) Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA 289, 2104-2112.
60. Hebert, P. C., Wells, G., Blajchman, M. A., Marshall, J., Martin, C., Pagliarello, G., Tweeddale, M., Schweitzer, I., Yetisir, E. (1999) A multicentre randomized controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. N. Engl. J. Med. 340, 409-417.
61. Kress, J. P., Pohlman, A. S., O'Connor, M. F., Hall, J. B. (2000) Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N. Engl. J. Med. 342, 1471-1477.
62. Chastre, J., Fagon, J. Y., Soler, P., Bornet, M., Domart, Y., Trouillet, J. L., Gibert, C., Hance, A. J. (1988) Diagnosis of nosocomial bacterial pneumonia in intubated patients undergoing ventilation: comparison of the usefulness of bronchoalveolar lavage and protected specimen brush. Am. J. Med. 85, 499-506.
63. Vincent, J-L., Sakr, Y., Sprung, C. L., Ranieri, V. M., Reinhart, K., Gerlach, H., Moreno, R., Carlet, J., Le Gall, R., Payen, D. (2006) Sepsis in European intensive care units: results of the SOAP study. Crit. Care Med. 34, 344-353.
64. Dellinger, R. P., Carlet, J. M., Masur, H., Gerlach, H., Calandra, T., Cohen, J., Moreno, R., Carlet, J., Le Gall, R., Payen, D. (2004) Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 32, 858-873.
65. Schwieterman, W., Roberts, R. (1997) FDA perspective on study design for therapies for severe sepsis. Sepsis 1, 69.
66. Abraham, E., Anzueto, A., Gutierrez, G., Tessler, S., San Pedro, G., Wunderink, R., Dal Nogare, A., Nasraway, S., Berman, S., Cooney, R., et al. (1998) Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351, 929-933.
67. Lopez, A., Lorente, J. A., Steingrub, J., Bakker, J., McLuckie, A., Willatts, S., Brockway, M., Anzueto, A., Holzapfel, L., Breen, D., et al. (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32, 21-30.
68. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A. L., Beale, R., Svoboda, P., Laterre, P. F., Simon, S., et al. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238-247.
69. Perl, T. M., Dvorak, L., Hwang, T., Wenzel, R. P. (1995) Long-term survival and function after suspected gram-negative sepsis. JAMA 274, 338-345.
70. Yende, S., Angus, D. C., Ali, I. S., Somes, G., Newman, A. B., Bauer, D., Garcia, M., Harris, T. B., Kritchevsky, S. B. (2007) Influence of comorbid conditions on long-term mortality after pneumonia in older people. J. Am. Geriatr. Soc. 55, 518-525.
71. Cohen, J., Guyatt, G., Bernard, G. R., Calandra, T., Cook, D., Elebourne, D., Marshall, J., Nunn, A., Opal, S. (2001) New strategies for clinical trials in patients with sepsis and septic shock. Crit. Care Med. 29, 880-886.
72. Marshall, J. C., Vincent, J. L., Guyatt, G., Angus, D. C., Abraham, E., Bernard, G., Bombardier, C., Calandra, T., Jorgensen, H. S., Sylvester, R., Boers, M. (2005) Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit. Care Med. 33, 1708-1716.
73. Mackillop, W. J., O'Sullivan, B., Gospodarowicz, M. (1998) The role of cancer staging in evidence-based medicine. Cancer Prev. Control 2, 269-277.
74. Marshall, J. C., Vincent, J-L., Fink, M. P., Cook, D. J., Rubenfeld, G., Foster, D., Faist, E., Reinhart, K. (2003) Measures, markers, and mediators: towards a staging system for clinical sepsis. Crit. Care Med. 31, 1560-1567.
75. Levy, M. M., Fink, M., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J-L., Ramsay, G. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250-1256.
76. Sørensen, T. I., Nielsen, G. G., Andersen, P. K., Teasdale, P. W. (1988) Genetic and environmental influences on premature death in adult adoptees. N. Engl. J. Med. 318, 727-732.
77. Holmes, C. L., Russell, J. A., Walley, K. R. (2003) Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest 124, 1103-1115.
78. Mira, J-P., Cariou, A., Grall, F., Delclaux, C., Losser, M-R., Heshmati, F., Cheval, C., Monchi, M., Teboul, J-L., Riche, F., et al. (1999) Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. JAMA 282, 561-568.
79. Lee, Y. H., Rho, Y. H., Choi, S. J., Ji, J. D., Song, G. G. (2006) Association of TNF-α -308 G/A polymorphism with responsiveness to TNF-α-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol. Int. 27, 157-161.
80. Reinhart, K., Wiegand-Löhnert, C., Grimminger, F., Kaul, M., Withington, S., Treacher, D., Eckart, J., Willatts, S., Bouza, C., Krausch, D., et al. (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo- controlled, dose-ranging study. Crit. Care Med. 24, 733-742.
81. Marshall, J. C., Albertson, T. E., Barchuk, W., van Meter, L. (2001) Effect of anti-TNF antibody on organ-specific components of MOD score. Afelimomab Study Group. Am. J. Respir. Crit. Care Med. 163, A820.